

1 **Title: Industry payments to anesthesiologists in the United States**
2 **between 2014 and 2022**

3
4 Anju Murayama^{1,2*}
5

6 **Affiliations:**

7 ¹ School of Medicine, Tohoku University, Sendai City, Miyagi, Japan

8 ² Department of Population Health Science and Policy, Icahn School of Medicine at
9 Mount Sinai, New York City, NY, USA
10

11 *Corresponding author
12

13 **Correspondence**

14 Anju Murayama

15 School of Medicine, Tohoku University, 2-1 Seiryomachi, Aoba ward, Sendai City,
16 Miyagi, 980-0872, Japan

17 Telephone: 81-22-717-8006

18 Email address: ange21tera@gmail.com
19

20 **Conflicts of interest statement:**

21 None declared.
22

23 **Word counts, number of figures and tables, and reference counts:**

24 Word counts: 2958 words for main body and 245 words in abstract

25 Number of Figures and tables: 3 figures and 1 table.

26 Number of references: 51 references
27

28 **Funding statement:**

29 None declared.
30

31 **Author contribution:**

32 Anju Murayama: conceptualization; methodology; resource; software; formal analysis;
33 investigation; writing - original draft; writing - review & editing; visualization; study
34 administration
35

36 **Ethical approval information:**

37 Institutional board review and approval were not required for this study, as this study is
38 designed as a non-human subjects study of freely available public data.

39

40 **Key Words:**

41 Open Payments Database; Sunshine Act; United States; ethics; conflict of interest, pain
42 medicine

43

44 **Abstract:**

45 **Background:**

46 Financial relationships between physicians and the healthcare industry could be
47 beneficial to improve patient care, but could lead to conflicts of interest. However,
48 there was no study specifically evaluating the extent of financial relationships between
49 anesthesiologists and the healthcare industry in the United States.

50

51 **Methods**

52 Using the Open Payments Database between 2014 and 2022, this longitudinal cross-
53 sectional study examined the size, prevalence and trends of general (non-research)
54 payments made by the healthcare industry to all anesthesiologists in the United States.

55

56 **Results:**

57 Over the nine-year period, 67.0% of all anesthesiologists received general payments
58 totaling \$272.0 million over nine years, while 21.0% to 35.3% of anesthesiologists
59 received one or more general payments each year. Median annual general payments to
60 anesthesiologists ranged from \$57 to \$115. The top 1%, 5%, and 10% of
61 anesthesiologists received 73.4%, 90.3%, and 94.8% of all general payments,
62 respectively. There were no constant yearly trends in the total amounts and per-
63 anesthesiologist general payments between 2014 and 2019, but significant declines
64 occurred in 2020, likely due to the COVID-19 pandemic. Pain medicine physicians
65 received the highest median general payments of \$4,426 in nine-year combined total
66 amounts, followed by addiction medicine (\$431), critical care medicine (\$277), and
67 general anesthesiology (\$256).

68

69 **Conclusion:**

70 This study reveals significant financial relationships between the healthcare industry
71 and anesthesiologists, with a disproportionate concentration of payments among a
72 minority of anesthesiologists. While no clear trends in payments were evident before
73 the pandemic, there was a substantial reduction during the COVID-19 outbreak.

74

75 **Main body of the manuscript**

76 **Introduction**

77 While certain interactions between physicians and the healthcare industry, such as
78 sharing experiences and collaborating on research, can benefit patients through drug
79 and device development and improved care, they may also create conflicts of interest
80 among physicians.[1] To enhance transparency in these relationships, the United States
81 (US) enacted the Physician Payments Sunshine Act in 2010. This act requires
82 pharmaceutical and medical device manufacturers to disclose their financial
83 transactions with physicians on a federal online database, the Open Payments Database,
84 since 2014.[2] Utilizing this database, numerous previous studies have demonstrated
85 widespread financial relationships between physicians and the healthcare industry
86 across various specialties other than anesthesiology.[2-11]

87
88 Anesthesiologists are responsible for a considerable proportion of opioid prescriptions,
89 accounting for 8.9% of all opioid-related prescriptions in the US, with primary care
90 physicians and nurse practitioners prescribing the majority of opioids.[12-14] Prior
91 research has revealed that non-research payments to physicians from opioid
92 manufacturers were significantly associated with increased opioid prescriptions at the
93 individual physician level[13,15-18] and higher opioid overdose deaths at the county
94 level.[19] However, the extent of financial relationships between anesthesiologists and
95 the healthcare industry in the US has not been well-documented. This study aims to
96 assess the size and prevalence of industry payments to anesthesiologists.

97
98 **Methods**

99 ***Study design, participants, and data collection***

100 This longitudinal cross-sectional study examines the extent and trends of non-research
101 payments to all anesthesiologists in the US using the Open Payments Database.
102 Following the Physician Payments Sunshine Act, all pharmaceutical and medical
103 device companies are required to disclose financial transfers exceeding \$100 annually
104 or \$10 per payment to physicians, nurse practitioners (since 2021), and teaching
105 hospitals. The reported payments have been disclosed on the Open Payments Database
106 since August 2013, but full-year payment data have been available since 2014.

107
108 All anesthesiologists in the US were identified as physicians whose primary specialty
109 was anesthesiology and subspecialties, and their profile data were extracted from the
110 Centers for Medicare and Medicaid Services National Plan and Provider Enumeration

111 System database. All general payments to anesthesiologists were extracted from the
112 Open Payments Database from 2014 to 2022, matching their National Provider
113 Identifier number, as previously noted.[3,9,20,21]

114

115 ***Data analyses***

116 Descriptive analysis was conducted on the extracted payment data. For
117 anesthesiologists who received payments, per-anesthesiologist payments were
118 calculated. Additionally, yearly trends in the number of anesthesiologists receiving
119 payments and per-anesthesiologist payments were examined using population-
120 averaged generalized estimating equations (GEE) with robust adjustment at the
121 individual physician level. The trend in total amounts of annual payments was
122 examined with a linear regression model, adjusting for the impact of the COVID-19
123 pandemic using interrupted time series (ITS) analysis.[4,21-23] The annual number of
124 anesthesiologists receiving payments and per-anesthesiologist payments were
125 examined using a modified log-linked GEE model with Poisson distribution and
126 negative binomial GEE model, respectively.[3,9,20] General payments for royalties,
127 ownership interests, acquisitions, debt forgiveness, and long term medical supply or
128 device loan were excluded from the trend analysis, as only small number of
129 anesthesiologists received substantial amounts (royalties and ownership interest) or the
130 payment categories were newly introduced since 2021 data (acquisitions, debt
131 forgiveness, and long-term medical supply or device loan). As subgroup analyses, the
132 study performed the GEE trend analyses excluding anesthesiologists who were
133 deactivated and/or newly activated after 2014, to exclude new and retired physicians
134 from the study sample. Inflation in US dollars was adjusted to 2022-dollar values in all
135 analyses using the U.S. Bureau of Labor Statistics Consumer Price Index
136 calculator.[3,23]

137 Additionally, the payments data were analyzed by payment categories, anesthesiologist
138 subspecialties, and companies making payments. Differences in per-anesthesiologist
139 payment and likelihood to receive payments by subspecialty were evaluated with a chi-
140 square test and a Kruskal Wallis test. All data extraction and statistical analysis were
141 performed using Python 3.9.12 (Python Software Foundation, Beaverton, OR, USA),
142 Microsoft Excel, version 16.0 (Microsoft Corp., Redmond, WA, USA), and Stata
143 version 17.0 (StataCorp, College Station, TX, USA).

144

145 ***Ethical clearance***

146 Given that the publicly available data set per the Sunshine Act reporting guidelines,

147 Institutional board review and approval were not required for this study, as it was
148 designed as a non-human subjects study of freely available public data.

149

150 **Results**

151 Out of 61,305 anesthesiologists registered in the NPPES database, 67.0% (41,041)
152 received at least one general payment from 1373 companies between 2014 and 2022,
153 totaling \$271,950,702 in inflation-adjusted amounts. Median nine-year combined total
154 amounts of general payments per anesthesiologist were \$291 (interquartile range
155 [IQR]: \$108–\$974), while the mean was \$6,626 (standard deviation: \$66,792). The top
156 1%, 5%, and 10% of anesthesiologists received 73.4%, 90.3%, and 94.8% of all
157 general payments over the nine years, respectively (Figure 1).

158

159 ***Payment trends between 2014 and 2022***

160 Annual trends showed that 21.0% to 35.3% of anesthesiologists received one or more
161 general payments each year between 2014 and 2022. The total amounts of general
162 payments decreased from \$37 million in 2015 to \$33 million in 2019 and further to
163 \$21.7 million in 2020 during the COVID-19 pandemic. Median annual general
164 payments to anesthesiologists ranged from \$57 to \$115 (Table 1).

165

166 The GEE model indicated no constant trends in the amounts, counts, and per-
167 anesthesiologist general payments between 2014 and 2019 (Table 1). However, the
168 number of anesthesiologists with general payments increased by 1.8% (95%
169 confidence interval [95% CI]: 1.5–2.0, $p < 0.001$) each year. Total annual amounts of
170 general payments significantly decreased by 72.4% (95% CI: -84.4% to -60.4%,
171 $p < 0.001$) in 2020 compared to those between 2014 and 2019. Similarly, both the
172 number of anesthesiologists receiving general payments and per-anesthesiologist
173 payment amounts significantly decreased by 43.2% (95% CI: -44.2% to -42.1%,
174 $p < 0.001$) and 59.5% (95% CI: -65.2% to -52.9%, $p < 0.001$) in 2020, respectively.
175 However, there were significant recovery trends in all variables between 2020 and
176 2022.

177

178 Subgroup analyses excluding newly activated anesthesiologists showed similar trends
179 in the total annual amounts of payments and per-anesthesiologist payment amounts
180 (Supplemental Material 1). The number of anesthesiologists receiving general
181 payments slightly increased by 0.5% (95% CI: 0.3%–0.8%, $p < 0.001$), indicating that
182 the increasing trend observed in the previous GEE model was primarily due to new

183 anesthesiologists receiving general payments.

184

185 ***Payments by category and company***

186 In payment amount, speaking compensation not related to continuing medical
187 education (CME) program accounted for the largest proportion (29.3%) of all general
188 payments, followed by consulting payments (20.9%). Food and beverage payments
189 made up 15.5% of all general payments but were received by 66.2% of
190 anesthesiologists.

191

192 In payment amounts, speaking compensation not related to continuing medical
193 education (CME) program is the largest payment categories occupying 29.3% (\$79.7
194 million) of all general payments, followed by consulting payments (20.9%, \$56.8
195 million) (Supplemental Material 2). Food and beverage payments accounted for 15.5%
196 (\$42.2 million) of all general payments, but were received by 66.2% of all
197 anesthesiologists and the number of food and beverage payments occupied 87.5%
198 (1,183,671) of general payments. Only 3.2% (1,944) and 4.9% (2,988) of
199 anesthesiologists received the speaking compensations not related to CME program
200 and consulting payments, respectively. The highest per-payment values were \$111,162
201 in acquisition payments, \$31,687 in royalty or license payments, \$24,662 in ownership
202 payments. Per-payment value were \$2,976 in consulting payments and \$2,772 in
203 speaking compensations for non-CME program, while it was \$36 in food and beverage
204 payments.

205

206 Among 1373 companies, the top 10 and 30 companies accounted for 41.9% (\$113.9
207 million) and 67.8% (\$184.5 million) of all general payments, respectively
208 (Supplemental Material 3). Pacira Pharmaceuticals made the largest general payments
209 (\$19.8 million), followed by Medtronic USA (\$15.1 million), Boston Scientific (\$13.7
210 million), Halyard Health (\$11.2 million), and Abbott Laboratories (\$11.0 million).

211

212 ***Payments by subspecialty***

213 The proportion of anesthesiologists receiving general payments over the nine-year
214 period was highest in pain medicine (89.5%), followed by addiction medicine (69.5%)
215 and general anesthesiology (65.7%) (Figure 2). Pain medicine physicians received the
216 highest median general payments of \$4,426 (IQR: \$1,077–\$12,881), followed by
217 addiction medicine (\$431 [IQR: \$177–\$2,030]), critical care medicine (\$277 [IQR:
218 \$113–\$1,081]), and general anesthesiology (\$256 [IQR: \$98–\$717]) (Figure 3). There

219 were significant differences by subspecialty in the proportion of anesthesiologists
220 receiving one or more general payments over the nine-years ($p < 0.001$ in chi-square
221 test) and per-anesthesiologist general payments ($p < 0.001$ in Kruskal Wallis test). While
222 pain medicine physicians were 6.8% (4,164 out of 61,305) of all anesthesiologists
223 included in this study, they received 38.1% (\$103.6 million) of all general payments
224 from the healthcare industry.

225

226 Regarding payment trends by subspecialty, only pain medicine exceeded the majority
227 of anesthesiologists receiving general payments each year (Supplemental Material 4).
228 Median per-anesthesiologist general payments were the highest in pain medicine
229 (\$326–\$732), followed by addiction medicine (\$71–\$196) and critical care medicine
230 (\$69–\$139).

231

232 **Discussion**

233 This study is the first analysis to assess the magnitude and extent of general payments
234 provided to all anesthesiologists in the United States. The findings demonstrate that
235 more than \$271 million in general payments were made to 67.0% of all
236 anesthesiologists over the nine-year period, with only a minority of anesthesiologists
237 receiving payments each year. Moreover, a large proportion of the general payments
238 were received by a small number of anesthesiologists. The study also reveals
239 differences in general payment patterns within anesthesiology subspecialties, with pain
240 medicine physicians receiving the highest median general payments, primarily from
241 pharmaceutical companies marketing opioids. Pain medicine physicians received more
242 than 17 times higher general payments in median amounts than general
243 anesthesiologists. Although there were no continuing trends in payments between 2014
244 and 2019, both the number of anesthesiologists receiving general payments and per-
245 anesthesiologist general payments significantly decreased in 2020. Compared to the
246 findings from previous studies, this study would provide important insight into the
247 transparency of the financial relationship between anesthesiologists and the healthcare
248 industry.

249

250 First, this study found that the median annual general payments to anesthesiologists
251 ranged from \$57 to \$115 each year. Compared to previous studies, this study indicates
252 that anesthesiologists received fewer general payments from the healthcare industry
253 than other medical specialists in the US. For instance, Marshall and her colleagues
254 reported that median general payments per physician were \$186 in family medicine

255 physicians, \$251 in general surgeons, \$453 in colorectal surgeons, and \$860 in thoracic
256 surgeons in 2015.[2] Another studies based on the same study design among internal
257 medicine subspecialties reported that median annual general payments were \$197 to
258 \$220 in infectious disease specialists[6], \$379 to \$440 in pulmonologists[3], \$395–
259 \$590 in allergy and clinical immunology[4], \$632 in medical oncology[24], \$730 to
260 \$812 in rheumatologists[21], \$725 to \$847 in cardiologists.[22] Additionally, given
261 mean annual wage for anesthesiologists was \$302,970 according to 2022 estimates
262 from the U.S. Bureau of Labor Statistics,[25] the majority of anesthesiologists have not
263 received large general payments compared to their annual salary as an anesthesiologist.

264

265 An intriguing observation from this study is the significant variation in general
266 payments among anesthesiology subspecialties. Notably, pain medicine physicians
267 received substantially higher median general payments compared to other
268 anesthesiologists and even certain specialists from different medical fields. Median
269 nine-year payment amounts to pain medicine physicians were 17.3 times larger than
270 those to general anesthesiologists (\$4,426 vs \$256). Additionally, compared to other
271 specialists, median annual general payments to pain medicine physicians (\$326–\$732)
272 were as same as or higher than several surgery and internal medicine specialists such
273 as general surgeons,[2] pulmonologists,[3] allergists,[4] and medical oncologists.[2,24]
274 These large payments to pain medicine physicians were made by pharmaceutical
275 companies marketing opioids in the United States, such as INSYS Therapeutics,
276 Depomed, Purdue Pharma, and Pfizer. Intense marketing activities by opioid
277 manufacturers to physicians and healthcare community have been well documented
278 since the early 2000s.[15-19,26] Hadland et al. reported that pain medicine physicians
279 received the third largest general payments related to opioid of all specialists between
280 2013 and 2015.[18] This finding warrants further investigation and raises questions
281 about the potential influence of these financial relationships on pain medicine practice
282 and decision-making. Given the well-documented association between opioid-related
283 payments and increased opioid prescriptions, healthcare costs,[17,19,26] and opioid
284 overdose deaths,[19] it is crucial for pain medicine physicians to be cautious and
285 transparent in their financial interactions with opioid manufacturers. While this study
286 does not establish any undue influence of industry payments on anesthesiologists, it
287 underscores the importance of vigilance and adherence to conflicts of interest
288 guidelines to maintain the integrity of clinical, education, and research practices.[1,27-
289 29] Further research is warranted to explore the implications of these financial
290 interactions on clinical decision-making, healthcare practices, and patient outcomes.

291

292 Furthermore, only the top 1% and 10% of anesthesiologists received nearly three
293 fourths and 95% of all general payments, respectively. This finding is consistent with
294 many previous studies in this research field.[3,5,8-11,21-23,30-34] Feng et al. reported
295 that the top 10% of dermatologists received more than 90% of all general payments
296 from the healthcare industry in 2014.[8] The top 10% of pulmonologists received
297 83.7% of all general payments between 2013 and 2021.[3] As shown in previous
298 studies, the healthcare industry made the large amounts of general payments to the
299 small fraction of physicians who are in leading positions such as clinical guideline
300 authors,[7,32,35-37] journal editors,[32,37-40] society board members,[32,41] and
301 principal investigators of industry-sponsored clinical trials.[28,42] These influential
302 physicians are called key opinion leaders.[42,43] Although some studies positively
303 stated the role of key opinion leaders who are supported by the healthcare industry
304 when they advocate as an independent expert for better, cheaper and safer products on
305 behalf of patients and healthcare communities,[33] most of previous cases have not
306 shown such positive effects. Instead, financial conflicts of interest between healthcare
307 industry and key opinion leaders have questioned the influence of experts on
308 recommendations and practices.[27,44-47] Current global standards for managing
309 conflicts of interest require these influential physicians such as clinical guideline
310 authors and journal editors to minimize their financial interactions with the healthcare
311 industry and at least to be transparent in their relationships with the healthcare industry.
312 Nevertheless, Wyssa et al. found that there was no disclosure of authors' conflicts of
313 interest in 36% of clinical guidelines published in ten high-impact anesthesiology
314 academic journals between 2008 and 2018.[48] Additionally, some studies in other
315 specialties found that there were large amounts of undeclared and under-declared
316 financial relationships between the healthcare industry and influential physicians.[49]
317 Further transparency in financial relationships between the healthcare industry and the
318 influential physicians is needed. Future studies should evaluate the extent and accuracy
319 of disclosed financial relationships between the healthcare industry and influential
320 anesthesiologists.

321

322 Another notable aspect of this study is its evaluation of trends in general payments
323 over time. Despite the implementation of the Open Payments Database to increase
324 transparency in physicians-industry relationships, some experts predicted that
325 increased transparency and increased public pressure and scrutiny would lead to a
326 decrease in physicians-industry financial relationships for non-research purposes.[50]

327 This study found limited changes in the general payments patterns between 2014 and
328 2019. This observation would raise questions about the effectiveness of the Open
329 Payments Database in altering anesthesiologists-industry financial relationships.
330 However, the COVID-19 pandemic had a profound impact on general payments in
331 2020, with a substantial decrease in both the amounts and the number of
332 anesthesiologists receiving payments. This finding is consistent with previous studies
333 in other specialties and overall.[6,21,22,30,31,51] Inoue et al. found that the amounts
334 of general payments decreased by more than 44% overall in 2020 compared to those in
335 2019.[51] Santamaria et al. reported that general payments to surgeons decreased by
336 about 50% in 2020.[30] This decline in general payments to anesthesiologists can be
337 attributed to the pandemic-related restrictions and measures that disrupted traditional
338 marketing strategies and in-person interactions. Interestingly, the industry seemed to
339 adapt quickly to the changing landscape, as evidenced by the significant recovery
340 trends in payments between 2020 and 2022, while the total amount of general
341 payments to anesthesiologists in 2022 was still about 70% of those before the
342 pandemic (\$23.8 million in 2022 vs \$33.0 million in 2019). This adaptation likely
343 involved a shift towards utilizing online platforms and virtual engagement to maintain
344 communication and marketing efforts during the pandemic.[21,22,30] Considering the
345 current significant downsizing of pharmaceutical representatives, the use of online
346 platforms and virtual marketing will continue even after the pandemic.

347
348 The limitations of this study include the possibility of errors in public databases, such
349 as the NPPES and Open Payments Database, as pointed out in previous studies.[3,21]
350 Second, there would be unmeasured confounding factors that may impact trends in
351 general payments to anesthesiologists.[3,9] Third, there would be differences in the
352 number of anesthesiologists between the U.S. Centers for Medicare & Medicaid
353 Services NPPES database and other databases such as the American Board of
354 Anesthesiology and the Association of American Medical Colleges databases, as these
355 are structured based on different methods and physicians self-declared their primary
356 specialty in the NPPES database even though they did not have board-certification as
357 an anesthesiologist.[2,20] Fourth, the amounts of general payments to anesthesiologists
358 would be influenced by non-measured anesthesiologists' demographic factors such as
359 physician age, workplace type, position, and graduated school. However, these
360 variables are not available from the NPPES and the Open Payments Database. Finally,
361 there would be unmeasured interactions such as free drug samples not covered by the
362 Open Payments Database and the Physician Payments Sunshine Act.

363

364 In summary, this study reveals that over \$271 million in general payments were made
365 to 67.0% of anesthesiologists between 2014 and 2022, with only a minority receiving
366 these payments annually. The majority of payments were received by the small group
367 of anesthesiologists. While there were no significant trends in payments from 2014 to
368 2019, the COVID-19 pandemic caused a notable decline in 2020. However, payments
369 showed a remarkable recovery between 2020 and 2022. These findings emphasize the
370 importance of transparency in financial relationships and the need to address potential
371 conflicts of interest. Continued efforts to promote transparency are essential for
372 maintaining trust in healthcare practices.

373

374 **Acknowledgments**

375 I would like to thank Ms. Megumi Aizawa for her dedicated support of my research. I
376 declared no financial conflicts of interest and did not receive any financial support for
377 this study from any entity. For proofreading parts of the presented text, I used the
378 freely available pre-trained ChatGPT (version 3.5) model developed by OpenAI in
379 order to check and proofread the manuscript for language, spelling and grammatical
380 errors. I checked and edited the text for unintended plagiarism, and verified all facts
381 and values that I used from the ChatGPT outputs before the manuscript submission.

382

383 **References**

- 384 1. Institute of Medicine. *Conflict of Interest in Medical Research, Education, and*
385 *Practice*. Washington, DC: The National Academies Press, 2009.
- 386 2. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-
387 Gluth JA. Types and Distribution of Payments From Industry to Physicians in
388 2015. *Jama* 2017; **317**: 1774-84.
- 389 3. Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A Nine-year
390 Investigation of Healthcare Industry Payments to Pulmonologists in the United
391 States. *Ann Am Thorac Soc* 2023.
- 392 4. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Industry payments
393 to allergists and clinical immunologists in the United States during the
394 coronavirus disease 2019 pandemic. *Ann Allergy Asthma Immunol* 2022; **129**:
395 635-6.
- 396 5. Annapureddy A, Murugiah K, Mingos KE, Chui PW, Desai N, Curtis JP.
397 Industry Payments to Cardiologists. *Circ Cardiovasc Qual Outcomes* 2018; **11**:
398 e005016.

- 399 6. Murayama A, Nakano K, Kamamoto S, et al. Trend in industry payments to
400 infectious disease physicians in the United States: a seven-year analysis of
401 nonresearch payments from the Open Payments Database between 2014 and
402 2020. *Clin Microbiol Infect* 2022; **28**: 1655 e1- e4.
- 403 7. Nusrat S, Syed T, Nusrat S, Chen S, Chen WJ, Bielefeldt K. Assessment of
404 Pharmaceutical Company and Device Manufacturer Payments to
405 Gastroenterologists and Their Participation in Clinical Practice Guideline
406 Panels. *JAMA Netw Open* 2018; **1**: e186343.
- 407 8. Feng H, Wu P, Leger M. Exploring the Industry-Dermatologist Financial
408 Relationship: Insight From the Open Payment Data. *JAMA Dermatol* 2016;
409 **152**: 1307-13.
- 410 9. Murayama A, Hirota S. Industry payments to pathologists in the USA between
411 2013 and 2021. *J Clin Pathol* 2023.
- 412 10. Muffly TM, Giamberardino WL, Guido J, Weterings R, Bastow B, Sheeder J.
413 Industry Payments to Obstetricians and Gynecologists Under the Sunshine Act.
414 *Obstet Gynecol* 2018; **132**: 9-17.
- 415 11. Parikh K, Fleischman W, Agrawal S. Industry Relationships With Pediatricians:
416 Findings From the Open Payments Sunshine Act. *Pediatrics* 2016; **137**:
417 e20154440.
- 418 12. Guy GP, Jr., Zhang K. Opioid Prescribing by Specialty and Volume in the U.S.
419 *Am J Prev Med* 2018; **55**: e153-e5.
- 420 13. Inoue K, Figueroa JF, Orav EJ, Tsugawa Y. Association between industry
421 payments for opioid products and physicians' prescription of opioids:
422 observational study with propensity-score matching. *J Epidemiol Community*
423 *Health* 2020; **74**: 647-54.
- 424 14. Agarwal A, Roberts A, Dusetzina SB, Royce TJ. Changes in Opioid Prescribing
425 Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries
426 From 2013 to 2017. *JAMA Oncology* 2020.
- 427 15. Hollander MA, Donohue JM, Stein BD, Krans EE, Jarlenski MP. Association
428 between opioid prescribing in Medicare and pharmaceutical company gifts by
429 physician specialty. *Journal of general internal medicine* 2020; **35**: 2451-8.
- 430 16. Hadland SE, Cerdá M, Li Y, Krieger MS, Marshall BDL. Association of
431 Pharmaceutical Industry Marketing of Opioid Products to Physicians With
432 Subsequent Opioid Prescribing. *JAMA Internal Medicine* 2018; **178**: 861-3.
- 433 17. Zezza MA, Bachhuber MA. Payments from drug companies to physicians are
434 associated with higher volume and more expensive opioid analgesic prescribing.

- 435 *PLoS One* 2018; **13**: e0209383.
- 436 18. Hadland SE, Krieger MS, Marshall BDL. Industry Payments to Physicians for
437 Opioid Products, 2013–2015. *American Journal of Public Health* 2017; **107**:
438 1493-5.
- 439 19. Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerdá M. Association of
440 Pharmaceutical Industry Marketing of Opioid Products With Mortality From
441 Opioid-Related Overdoses. *JAMA Network Open* 2019; **2**: e186007-e.
- 442 20. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in
443 Industry Payments to Physicians in the United States From 2014 to 2018. *Jama*
444 2020; **324**: 1785-8.
- 445 21. Murayama A, Kamamoto S, Higuchi K, Shigeta H, Ozaki A. Trend in Industry
446 Payments to Rheumatologists in the United States During the COVID-19
447 Pandemic Between 2013 and 2021. *J Rheumatol* 2023; **50**: 575-7.
- 448 22. Murayama A, Kamamoto S, Shigeta H, Ozaki A. Industry Payments During the
449 COVID-19 Pandemic to Cardiologists in the United States. *CJC Open* 2023; **5**:
450 253-5.
- 451 23. Murayama A. Industry-sponsored research funding to infectious disease
452 physicians in the United States between 2013 and 2021. *Clin Microbiol Infect*
453 2023.
- 454 24. Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA.
455 Distribution and Patterns of Industry-Related Payments to Oncologists in 2014.
456 *JNCI: Journal of the National Cancer Institute* 2016; **108**.
- 457 25. U.S. Bureau of Labor Statistics. Occupational Employment and Wage Statistics,
458 2022. <https://www.bls.gov/oes/current/oes291211.htm> (accessed July 20/2023).
- 459 26. Fleischman W, Agrawal S, Gross CP, Ross JS. Association of Pharmaceutical
460 Manufacturer Payments to Physicians and Prescribing Dosage of Opioids. *J*
461 *Gen Intern Med* 2019; **34**: 1074-6.
- 462 27. Nejstgaard CH, Bero L, Hrobjartsson A, et al. Association between conflicts of
463 interest and favourable recommendations in clinical guidelines, advisory
464 committee reports, opinion pieces, and narrative reviews: systematic review.
465 *BMJ* 2020; **371**: m4234.
- 466 28. Ahn R, Woodbridge A, Abraham A, et al. Financial ties of principal
467 investigators and randomized controlled trial outcomes: cross sectional study.
468 *BMJ* 2017; **356**: i6770.
- 469 29. Dubois MY. American Academy of Pain Medicine Ethics Council Statement on
470 Conflicts of Interest: Interaction between Physicians and Industry in Pain

- 471 Medicine. *Pain Medicine* 2010; **11**: 257-62.
- 472 30. Santamaria-Barria JA, Nelson H, Jiang H, et al. Open Payments Data Analysis
473 of General and Fellowship-trained Surgeons Receiving Industry General
474 Payments from 2016 to 2020: Payment Disparities and COVID-19 Pandemic
475 Impact. *Ann Surg* 2023.
- 476 31. Khunte M, Zhong A, Khunte A, et al. Industry Payments to Radiologists During
477 the Last 5 Years and Impact of COVID-19 Pandemic. *J Am Coll Radiol* 2023;
478 **20**: 597-604.
- 479 32. Wright K, Meyers DE, Chisamore TM, et al. Industry Relationships With
480 Medical Oncologists: Who Are the High-Payment Physicians? *JCO Oncology
481 Practice* 2022; **18**: e1164-e9.
- 482 33. Storino A, Vigna C, Polanco-Santana JC, et al. Disparities in industry funding
483 among Colorectal Surgeons: a cross-sectional study. *Surgical Endoscopy* 2022;
484 **36**: 6592-600.
- 485 34. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Trends in Industry
486 Payments to Diabetologists and Endocrinologists in the United States During
487 the COVID-19 Pandemic. *Cureus* 2022; **14**: e32643.
- 488 35. Tabatabavakili S, Khan R, Scaffidi MA, Gimpaya N, Lightfoot D, Grover SC.
489 Financial Conflicts of Interest in Clinical Practice Guidelines: A Systematic
490 Review. *Mayo Clin Proc Innov Qual Outcomes* 2021; **5**: 466-75.
- 491 36. Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Letter to the editor:
492 Are clinical practice guidelines for hepatitis C by the American Association for
493 the Study of Liver Diseases and Infectious Diseases Society of America
494 evidence based? Financial conflicts of interest and assessment of quality of
495 evidence and strength of recommendations. *Hepatology* 2022; **75**: 1052-4.
- 496 37. Kamamoto S, Murayama A, Kusumi E, et al. Evaluation of financial
497 relationships between Japanese certified pediatric hematologist/oncologists and
498 pharmaceutical companies: a cross-sectional analysis of personal payments
499 from pharmaceutical companies between 2016 and 2019. *Pediatr Blood Cancer*
500 2022; **69**: e29891.
- 501 38. Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US
502 pharmaceutical and medical device manufacturers to US medical journal
503 editors: retrospective observational study. *BMJ* 2017; **359**: j4619.
- 504 39. Nguyen D-D, Murad L, Nguyen AX-L, et al. Industry Payments to American
505 Editorial Board Members of Major Urology Journals. *European Urology* 2023.
- 506 40. Murayama A, Mamada H, Shigeta H, et al. Financial Relationships Between

507 Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and
508 2019. *JCR: Journal of Clinical Rheumatology* 2023;
509 10.1097/RHU.0000000000001922.

510 41. Murayama A, Kamamoto S, Kawashima M, et al. Cross-sectional analysis of
511 pharmaceutical payments to Japanese board-certified gastroenterologists
512 between 2016 and 2019. *BMJ Open* 2023; **13**: e068237.

513 42. Scher JU, Schett G. Key opinion leaders - a critical perspective. *Nat Rev*
514 *Rheumatol* 2021; **17**: 119-24.

515 43. Moynihan R. Key opinion leaders: independent experts or drug representatives
516 in disguise? *BMJ* 2008; **336**: 1402-3.

517 44. Johnson L, Stricker RB. Attorney General forces Infectious Diseases Society of
518 America to redo Lyme guidelines due to flawed development process. *J Med*
519 *Ethics* 2009; **35**: 283-8.

520 45. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial and
521 Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines
522 Authors for Allergic Rhinitis. *Otolaryngol Head Neck Surg* 2022; **166**: 869-76.

523 46. Steinbrook R. Guidance for guidelines. *N Engl J Med* 2007; **356**: 331-3.

524 47. McCoy MS, Pagán O, Donohoe G, Kanter GP, Litman RS. Conflicts of Interest
525 of Public Speakers at Meetings of the Anesthetic and Analgesic Drug Products
526 Advisory Committee. *JAMA Intern Med* 2018; **178**: 996-7.

527 48. Wyssa D, Tramèr MR, Elia N. Reporting of conflicts of interest and of
528 sponsorship of guidelines in anaesthesiology. A cross-sectional study. *PLoS*
529 *One* 2019; **14**: e0212327.

530 49. Taheri C, Kirubarajan A, Li X, Lam ACL, Taheri S, Olivieri NF. Discrepancies
531 in self-reported financial conflicts of interest disclosures by physicians: a
532 systematic review. *BMJ Open* 2021; **11**: e045306.

533 50. Pham-Kanter G. Act II of the Sunshine Act. *PLoS Med* 2014; **11**: e1001754.

534 51. Inoue K, Figueroa JF, Kondo N, Tsugawa Y. Changes in industry marketing
535 payments to physicians during the covid-19 pandemic: quasi experimental,
536 difference-in-difference study. *BMJ Medicine* 2022; **1**: e000219.

537
538
539

540 Table 1. General payments to anesthesiologists between 2014 and 2022


541

| Variables | Payment year | | | | | | | | | | Relative annual average percentage change (95% confidence interval), % ^b | | |
|---|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|--------------------------------|---|---------------------------------|--|
| | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2014-2019 | 2014-2019 vs 2020-2022 | 2020-2022 | |
| Total payment amounts, \$ | 30,201,179 | 36,998,756 | 35,662,138 | 33,336,258 | 33,964,108 | 32,988,544 | 21,705,999 | 23,302,673 | 23,791,047 | 0.8 (-2.6 to 4.3) | -72.4 (-84.4 to -60.4)* | 9.9 (5.1 – 14.7)* | |
| Number of physicians with payments, n (%) | 17,061 (27.8) | 18,177 (29.7) | 21,642 (35.3) | 19,466 (31.8) | 19,215 (31.3) | 19,245 (31.4) | 12,887 (21.0) | 16,277 (26.6) | 17,709 (28.9) | 1.8 (1.5 – 2.0)* | -43.2 (-44.2 to -42.1)* | 14.7 (13.8 – 15.6)* | |
| Payments per physician, \$ ^c | | | | | | | | | | | | | |
| Median (IQR) | 112 (33–280) | 115 (35–306) | 115 (34–282) | 104 (32–270) | 99 (30–255) | 109 (30–255) | 57 (22–197) | 74 (25–213) | 68 (24–211) | 0.7 (-2.4 to 3.9) ^c | -59.5 (-65.2 to -52.9)* ^c | 17.2 (9.7 – 25.1)* ^c | |
| Average (SD) | 1,770 (16,773) | 2,035 (26,148) | 1,648 (13,435) | 1,713 (14,203) | 1,768 (15,892) | 1,714 (19,874) | 1,684 (32,580) | 1,432 (14,750) | 1,343 (17,421) | | | | |

542 Legend: ^a Per-physician payment was calculated among physicians receiving payments. ^b General payments for royalties, ownership
543 interests, acquisitions, debt forgiveness, and long-term medical supply or device loan were excluded from the trend analysis, as only
544 small number of anesthesiologists received substantial amounts (royalties and ownership interest) or the payment categories were newly
545 introduced since 2021 data (acquisitions, debt forgiveness, and long-term medical supply or device loan). ^c These values were estimated
546 relative annual average percentage change among all anesthesiologists registered in the NPPES database including those who did not
547 receive any payments.

548 *p<0.001. Abbreviations: 95% confidence interval (95% CI), interquartile range (IQR), SD (standard deviation)

549




550

551

Figure 1. Concentration of general payments to anesthesiologists between 2014 and 2022.

552




553


554


555

Figure 2. Proportions of anesthesiologists receiving at least one general payment between 2014 and 2022 by subspecialty.




556
557 Figure 3. Median general payments per anesthesiologist among anesthesiologists who received general payments between 2014 and
558 2022 by subspecialty.





medRxiv preprint doi: <https://doi.org/10.1101/2023.07.24.23290096>; this version posted July 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



medRxiv preprint doi: <https://doi.org/10.1101/2023.07.24.23290096>; this version posted July 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

